Clinicopathological differences and correlations between right and left colon cancer

doi:10.12998/wjcc.v8.i8.1424

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8635)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-8) series, Tables (1-14) series.

Item

Count

PDF

515

WORD

201

HTML

4827

Figures (1-8)

361

Tables (1-14)

364

Sum=6268

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

847

Download

1520

Sum=2367

Apr 26, 2020 (publication date) through Feb 18, 2025

Times Cited of This Article

Times Cited (20)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Clin Cases. Apr 26, 2020; 8(8): 1424-1443
Published online Apr 26, 2020. doi: 10.12998/wjcc.v8.i8.1424

Table 1 Characteristics of right and left colon cancer patients

	LCC (n = 100)	RCC (n = 44)	P value
Male	64 (64.0%)	22 (50.0%)	P = 0.163
Female	36 (36.0%)	22 (50.0%)	P = 0.163
Age (mean ± SD) (yr)	65.4 (± 10.3)	65.5 (± 10.1)	P = 0.948
BMI (mean ± SD) (k/m²)	28.0 (± 4.4)	29.0 (± 6.6)	P = 0.225

RCC: Right colon cancer; LCC: Left colon cancer; BMI: Body mass index.

Table 2 Clinical presentation and comorbidities with statistically significant differences between left and right colon cancer patients

	LCC (n = 100), n (%)	RCC (n = 44), n (%)	P value
Anaemia	13 (13.1)	14 (31.8)	^aP = 0.008
Rectal bleeding	46 (46.5)	9 (20.5)	^aP = 0.003
Feeling of incomplete evacuation	26 (26.3)	5 (11.4)	^aP = 0.005
Coronary heart disease	9 (9.0)	9 (20.5)	^bP = 0.056
Diabetes mellitus	8 (8.2)	10 (13.6)	^aP = 0.016

^aStatistically significant at 0.05 level.

^bStatistically significant at 0.1 level. RCC: Right colon cancer; LCC: Left colon cancer.

Table 3 Disease stage, tumour size (T), infiltrated lymph nodes (N) and metastatic load (M) in right and left colon cancer patients at the time of diagnosis according to AJCC 8^th edition, 2017

		LCC (n = 100), n (%)	RCC (n = 44), n (%)	P value
Stage	I	7 (7.0)	0 (0)	P = 0.230
	II	13 (13.0)	8 (18.2)
	III	25 (25.0)	14 (31.8)
	IV	55 (55.0)	22 (50.0)
T	T₁-T₂	11 (11.0)	3 (6.8)	^bP = 0.088
	T₃	61 (61.0)	25 (56.8)
	T₄	13 (13.0)	13 (29.6)
	T_X	15 (15.0)	3 (6.8)
N	N₀	28 (28.0)	9 (20.5)	^aP = 0.039
	N₁	32 (32.0)	23 (52.3)
	N₂	24 (24.0)	5 (11.3)
	N_X	16 (16.0)	7 (15.9)
M	M₀	45 (45.0)	22 (50.0)	P = 0.446
	M_1a	40 (40.0)	13 (29.5)
	M_1b	15 (15.0)	9 (20.5)

^aStatistically significant at 0.05 level.

^bStatistically significant at 0.1 level. (P value = 0.039 refers to N₀-N₂). RCC: Right colon cancer; LCC: Left colon cancer.

Table 4 Histology, differentiation, and presence of necrosis, emboli (vascular and lymphatic) and perineural infiltration in patients with right and left colon cancer according to the World Health Organization 2019 classification

		LCC (n = 100), n (%)	RCC (n = 44), n (%)	P value
Histology	Adenocarcinoma	95 (95.0)	37 (84.1)	^aP = 0.046
	Mucinous	4 (4.0)	7 (15.9)
	Neuroendocrine	1 (1.0)	0 (0)
Differentiation	Low	19 (20.9)	19 (46.3)	^aP = 0.005
Differentiation	Moderate/High	72 (79.1)	22 (53.7)	^aP = 0.005
Necroses	No	53 (62.4)	24 (61.5)	P = 1.000
Necroses	Yes	32 (37.6)	15 (38.5)	P = 1.000
Emboli	No	68 (82.9)	34 (87.2)	P = 0.606
Emboli	Yes	14 (17.1)	5 (12.8)	P = 0.606
Perineural infiltration	No	71 (87.7)	36 (92.3)	P = 0.544
Perineural infiltration	Yes	10 (12.3)	3 (7.7)	P = 0.544

^aStatistically significant at 0.05 level. RCC: Right colon cancer; LCC: Left colon cancer.

Table 5 KRAS, NRAS, BRAF and MSI-related genes in right and left colon cancer patients

	LCC (n = 100), n (%)	RCC (n = 44), n (%)	Total, n (%)	P value
KRAS wild type	60 (63.8)	17 (42.5)	77 (57.5)	^aP = 0.036
KRAS mutant	34 (36.2)	23 (57.5)	57 (42.5)	^aP = 0.036
NRAS wild type	80 (95.2)	29 (100.0)	109 (96.5)	P = 0.571
NRAS mutant	4 (4.8)	0 (0)	4 (3.5)	P = 0.571
RAS wild type	56 (59.6)	17 (42.5)	73 (54.5)	P = 0.104
RAS mutant	38 (40.4)	23 (57.5)	61 (45.5)	P = 0.104
BRAF wild type	60 (93.8)	23 (82.1)	83 (90.2)	P = 0.125
BRAF mutant	4 (6.2)	5 (17.9)	9 (9.8)	P = 0.125
MSS	51 (94.4)	29 (93.5)	80 (94.1)	P = 1.000
MSI-H	3 (5.6)	2 (6.5)	5 (5.9)	P = 1.000

^aStatistically significant at 0.05 level. RCC: Right colon cancer; LCC: Left colon cancer; MSI: Microsatellite instability.

Table 6 Adjuvant and perioperative therapy across disease stages and locations

Stage	Location	FOLFOX	XELOX	RT-capecitabine	RT-capecitabine-XELOX	Total
II	LCC	3	5	5	-	13
II	RCC	3	5	-	-	8
III	LCC	3	11	-	11	25
III	RCC	2	12	-	-	14
Total	LCC	6	16	5	11	38
Total	RCC	5	17	-	-	22
	Total	11	33	5	11	60

RCC: Right colon cancer; LCC: Left colon cancer.

Table 7 Cox regression analysis of disease recurrence

	P value	HR	95%CI
KRAS wild-type/NRAS mutant (Ref cat)
KRAS mutant	^aP = 0.002	3.731	1.635-8.513
Presence of emboli	^aP = 0.025	3.221	1.161-8.938
Location	0.286
Histology	0.339
Sex	0.797
Age	0.336
Lymph node involvement	0.465
Grade	0.533
Necroses	0.911
Initial stage	0.216

^aStatistically significant at 0.05 level. HR: Hazard ratio; CI: Confidence interval.

Table 8 Administered chemotherapy regimens in the first-line setting according to primary tumour location

	FOLFOX, n (%)	FOLFIRI, n (%)	Cisplatin-etoposide (%)	Total, n (%)
LCC	61 (53.0)	21 (18.3)	1 (0.9)	83 (72.2)
RCC	19 (16.5)	13 (11.3)	-	32 (27.8)
Total	80 (69.5)	34 (29.6)	1 (0.9)	115 (100)

RCC: Right colon cancer; LCC: Left colon cancer.

Table 9 Administered antibodies in the first-line setting according to RAS mutation status and progression-free survival time

	RAS status	Bevacizumab, n (%)	PFS	Panitumumab, n (%)	PFS	Total, n (%)	PFS
LCC	RAS wild type	20 (17.6)	12.3	27 (23.7)	15.8	47 (41.3)	14.0
	RAS mutant	35 (30.7)	11.6	-	-	35 (30.7)	11.6
	Total	55 (48.3)	11.6	27 (23.7)	15.8	82 (72.0)	12.2
RCC	RAS wild type	4 (3.4)	22.2	8 (7.0)	5.5	12 (10.4)	13.8
	RAS mutant	20 (17.6)	10	-	-	20 (17.6)	10
	Total	24 (21.0)	12.6	8 (7.0)	5.5	32 (28.0)	12.5
Total		79 (69.3)	12	35 (30.7)	14.5	114 (100.0)	12.3

RCC: Right colon cancer, LCC: Left colon cancer, PFS: Progression free survival.

Table 10 Cox regression analysis of first-line chemotherapy

	P value	HR	95%CI
BRAF wild type		(Ref cat)
BRAF mutant	^aP = 0.040	2.454	1.044-5.772
KRAS/NRAS	0.202
Location	0.166
Histology	0.636
Sex	0.405
Age	0.906
Antibody	0.748
Initial stage	0.217

^aStatistically significant at 0.05 level. HR: Hazard ratio; CI: Confidence interval.

Table 11 Administered chemotherapy regimens in the second-line setting according to primary tumour location

	FOLFOX, n (%)	FOLFIRI, n (%)	Total, n (%)
LCC	19 (19.4)	55 (56.1)	74 (75.5)
RCC	8 (8.2)	16 (16.3)	24 (24.5)
Total	27 (27.6)	71 (72.4)	98 (100.0)

RCC: Right colon cancer; LCC: Left colon cancer.

Table 12 Administered antibodies in the second-line setting according to RAS mutation status and time to progression-free survival

	RAS status	Bevacizumab, n (%)	PFS	Panitumumab, n (%)	PFS	Aflibercept, n (%)	PFS	Total, n (%)	PFS
LCC	RAS wild type	16 (16.5)	7.4	20 (20.6)	8.1	10 (10.3)	6.8	46 (47.4)	7.9
	RAS mutant	9 (9.3)	9	-	-	19 (19.6)	9.3	28 (28.9)	9.0
	Total	25 (25.8)	7.4	20 (20.6)	8.1	29 (29.9)	8.2	74 (76.3)	8.2
RCC	RAS wild type	2 (2.1)	4.4	6 (6.2)	12.3	1 (1.0)	7.7	9 (9.3)	9.0
	RAS mutant	7 (7.3)	10.4	-	-	7 (7.3)	7.0	14 (14.4)	12.3
	Total	9 (9.3)	10.4	6 (6.2)	12.3	8 (8.3)	7.1	23 (23.4)	8.6
		34 (34.5)	9.0	26 (26.8)	9.7	37 (38.1)	7.6	97 (100)	8.6

RCC: Right colon cancer; LCC: Left colon cancer; PFS: Progression free survival.

Table 13 Overall survival depending on the combination of administered antibodies in first- and second-line chemotherapy

First line	Second line	Median OS (mo)	P value
Bevacizumab	Bevacizumab	58.4	P = 0.693
Panitumumab	Bevacizumab	44.9
Bevacizumab	Panitumumab	51.7
Panitumumab	Panitumumab	46.7
Bevacizumab	Aflibercept	44.0
Panitumumab	Aflibercept	62.3

OS: Overall survival.

Table 14 Cox regression analysis of overall survival

	P value	HR	95%CI
KRAS wild type/NRAS wild type		(Ref cat)
KRAS mutant	^aP = 0.017	2.313	1.162-4.605
Initial stage I-III		(Ref cat)
Initial stage IV	^aP < 0.001	4.036	1.922-8.475
BRAF	0.373
Location	0.937
Histology	0.259
Sex	0.602
Age	0.250
Lymph nodes	0.407
Differentiation grade	0.142
Presence of necrosis	0.375
Presence of emboli	0.783

^aStatistically significant at 0.05 level. HR: Hazard ratio; CI: Confidence interval.

Citation: Kalantzis I, Nonni A, Pavlakis K, Delicha EM, Miltiadou K, Kosmas C, Ziras N, Gkoumas K, Gakiopoulou H. Clinicopathological differences and correlations between right and left colon cancer. World J Clin Cases 2020; 8(8): 1424-1443
URL: https://www.wjgnet.com/2307-8960/full/v8/i8/1424.htm
DOI: https://dx.doi.org/10.12998/wjcc.v8.i8.1424